NCT06475274 - A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

September 11, 2025

Study Completion Date

September 11, 2025

Conditions

Kidney Injury Following Open-Chest Cardiac Surgery

Interventions

DRUG

RMC-035

Protein, a recombinant variant of A1M. Concentrate for solution for infusion.

DRUG

Placebo

Identical to RMC-035 intervention devoid of the active substance.

Trial Locations (19)

Research site 4, Montreal

Research site 5, Montreal

Research site 2, Québec

Research site 3, Saint John

Research site 1, Toronto

Research site 1, Hradec Králové

Research site 2, Prague

Research site 5, Dresden

Research site 3, Essen

Research site 6, Giessen

Research site 4, Halle

Research site 2, München

Research site 1, Münster

Research site 3, Barcelona

Research site 4, Córdoba

Research site 1, Madrid

Research site 2, Madrid

Research site 6, Pamplona

Research site 5, Santiago de Compostela